source
- Bristol Myers reports two Phase 3 successes for fibrosis and RayzeBio drugBristol Myers Squibb announced Monday that two of its late-stage trials have met primary endpoints. The first trial involved its fibrosis program, where the experimental therapy demonstrated the e…
- GSK allocates over $800 million to expand R&D and manufacturing hub in PennsylvaniaGSK announced it will invest more than $800 million to expand its presence in Pennsylvania, marking its second expansion in the state within two years. The funds will be used to build a new resear…